HWK-016, MUCIN-16-targeted ADC + Bevacizumab
Phase 1Recruiting 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
PROC
Conditions
PROC, Platinum Resistant Ovarian Cancer, Endometrial Cancer
Trial Timeline
Mar 15, 2026 → Feb 1, 2028
NCT ID
NCT07470853About HWK-016, MUCIN-16-targeted ADC + Bevacizumab
HWK-016, MUCIN-16-targeted ADC + Bevacizumab is a phase 1 stage product being developed by Whitehawk Therapeutics for PROC. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07470853. Target conditions include PROC, Platinum Resistant Ovarian Cancer, Endometrial Cancer.
What happened to similar drugs?
5 of 11 similar drugs in PROC were approved
Approved (5) Terminated (3) Active (4)
✅Remimazolam Tosilate for Injection + Remimazolam Tosilate for InjectionJiangsu Hengrui MedicineApproved
Hype Score Breakdown
Clinical
6
Activity
15
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07470853 | Phase 1 | Recruiting |
Competing Products
17 competing products in PROC